Ireland
# |
Name |
Return on Capital Employed (ROCE) |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
27.51%
|
Dec. 31, 2023 | USD 31.53 | -1.19% |
|
Ireland |
|
2 |
6.60%
|
Dec. 31, 2023 | USD 199.08 | -1.31% |
|
Ireland |
|
3 |
5.96%
|
Dec. 31, 2023 | USD 124.37 | -0.54% |
|
Ireland |
|
4 |
1.16%
|
Dec. 31, 2023 | USD 69.87 | -1.17% |
|
Ireland |
|
5 |
-18.88%
|
Dec. 31, 2023 | USD 10.60 | 9.39% |
|
Ireland |
|
6 |
-29.87%
|
Dec. 31, 2023 | USD 14.23 | -3.20% |
|
Ireland |
|
7 |
-118.03%
|
Dec. 31, 2023 | USD 7.90 | 2.73% |
|
Ireland |
|
8 |
-285.14%
|
Dec. 31, 2023 | USD 1.60 | 1.91% |
|
Ireland |
The Clinical Trials company in Ireland with the highest Return on Capital Employed (ROCE) is Alkermes plc (NasdaqGS: ALKS) at 27.51%.
The Clinical Trials company in Ireland with the lowest Return on Capital Employed (ROCE) is Iterum Therapeutics plc (NasdaqCM: ITRM) at -285.14%.
The top 10 Clinical Trials companies in Ireland by Return on Capital Employed (ROCE) are Alkermes plc, ICON Public Limited Company, Jazz Pharmaceuticals plc, Cosmo Pharmaceuticals N.V., GH Research PLC, Prothena Corporation plc, Avadel Pharmaceuticals plc and Iterum Therapeutics plc.
The bottom 10 Clinical Trials companies in Ireland by Return on Capital Employed (ROCE) are Iterum Therapeutics plc, Avadel Pharmaceuticals plc, Prothena Corporation plc, GH Research PLC, Cosmo Pharmaceuticals N.V., Jazz Pharmaceuticals plc, ICON Public Limited Company and Alkermes plc.